News Xvivo Perfusion AB

Equities

XVIVO

SE0004840718

Market Closed - Nasdaq Stockholm Other stock markets 11:29:51 2024-04-17 am EDT			5-day change	1st Jan Change
328 ^SEK	+1.08%		+14.89%	-0.46%

Apr. 11	Xvivo Perfusion AB Announces Results from Clinical Trial NIHP2019 for Heart Preservation Presented at ISHLT in Prague	CI
Mar. 16	Certain Shares of Xvivo Perfusion AB are subject to a Lock-Up Agreement Ending on 16-MAR-2024.	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Xvivo Perfusion : Results from XVIVO's clinical trial NIHP2019 for heart preservation presented at ISHLT in Prague	Apr. 11	PU
Results from XVIVO’s clinical trial NIHP2019 for heart preservation presented at ISHLT in Prague	Apr. 11	AQ
Xvivo Perfusion AB Announces Results from Clinical Trial NIHP2019 for Heart Preservation Presented at ISHLT in Prague	Apr. 11	CI
Xvivo Perfusion : Notice to AGM 2024	Mar. 21	PU
Xvivo Perfusion : SORP 2024	Mar. 21	PU
Xvivo Perfusion : Styrelsens 19-22 redogörelse (Eng)	Mar. 21	PU
NOTICE TO ATTEND THE ANNUAL GENERAL MEETING IN XVIVO PERFUSION AB (PUBL)	Mar. 21	AQ
Certain Shares of Xvivo Perfusion AB are subject to a Lock-Up Agreement Ending on 16-MAR-2024.	Mar. 15	CI
The first-ever transplantation with a donor heart transported across the Atlantic Ocean – made possible by the use of XVIVO’s heart technology	Feb. 29	AQ
Nordic Shares Moved Upward Thursday; Nokia Topped Leaders	Jan. 25	DJ
Transcript : Xvivo Perfusion AB, 2023 Earnings Call, Jan 25, 2024	Jan. 25
XVIVO presents Report on Operations 2023	Jan. 25	AQ
Xvivo Perfusion AB Reports Earnings Results for the Full Year Ended December 31, 2023	Jan. 25	CI
Xvivo Perfusion AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Jan. 25	CI
Nordic Stocks Decreased Wednesday; Kone B Posted Biggest Loss	Jan. 17	DJ
XVIVO reaches milestone in Italy: 1,200 lifesaving perfusions performed with Liver Assist	Dec. 22	AQ
XVIVO announces a write-down related to PrimECC of SEK 17 million not affecting cashflow or EBITDA	Dec. 14	AQ
Results from a Australian/New Zealand study using XVIVO’s heart technology published	Nov. 03	AQ
Xvivo Perfusion AB Announces Results from A Australian/New Zealand Study Using Xvivo's Heart Technology Published	Nov. 03	CI
Transcript : Xvivo Perfusion AB, Q3 2023 Earnings Call, Oct 24, 2023	23-10-24

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Xvivo Perfusion AB

Equities

XVIVO

SE0004840718

Summary

Filters